2002 - Pharmacist Digest

STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

STAT

SEPTEMBER 16, 2022

Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed in vivo, or inside the body — found that the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low- and high-dose cohort, respectively.

Opinion: What Rosalynn Carter understood about mental health

STAT

NOVEMBER 21, 2023

Often she was called upon to guide, inform, or brainstorm, as she did in 2002 when Mike Hogan, chair of President George W.

Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s

STAT

JANUARY 11, 2023

In 2002, toxicologist and neuropathologist Lilian Calderón-Garcidueñas, who grew up east of the metropolis and attended medical school in the city, decided to look at the brains of 40 dogs that had lived either in the city’s polluted valley or in the cleaner air of Tlaxcala, a state on its eastern edge.

Medical Schools

STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug

STAT

OCTOBER 31, 2023

Here’s the backstory: Enbrel was the centerpiece of a 2002 deal in which Amgen acquired another company called Immunex that had developed the medicine. But Public Citizen maintains Medicare officials should consider the ongoing cost of the patenting tactics when negotiating a price.

Drug Pricing

Watch: Blockbuster drug Humira has new competition. Here’s why that matters

STAT

FEBRUARY 13, 2023

Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.

Biosimilars

STAT+: Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts

STAT

SEPTEMBER 16, 2022

Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed inside the body — found the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low- and high-dose cohort, respectively.

Watch: Blockbuster drug Humira has new competition. Here’s why that matters

STAT

FEBRUARY 13, 2023

Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.

Biosimilars

How telehealth startups are trying to fill the menopause care vacuum

STAT

JULY 17, 2023

But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease.

First patient receives new engineered mRNA epigenetic

European Pharmaceutical Review

OCTOBER 28, 2022

revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. OTX-2002 is delivered via lipid nanoparticles (LNPs) and controls the expression of specific genes using epigenetics, a new era of medicine. .

Leprosy potentially endemic in Central Florida

Pharmaceutical Technology

AUGUST 16, 2023

The proportion of cases found in migrants to Florida has decreased significantly since 2002 while cases in US residents has risen.

Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

PharmaShots

MARCH 31, 2023

Shots: The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. The preliminary results from the monotx.

Immunity

Immunity Immunization

AGI Greenpac gets CCI approval to acquire Hindustan National Glass & Industries

Express Pharma

MARCH 18, 2023

As per the latest update, CCI has given its approval to the proposed combination under sub-section (1) of Section 31 of the Competition Act, 2002 vide its letter dated March 15, 2023. The detailed order of CCI is awaited.

Science Magazine names Dr Reddy’s among Top 20 employers in pharma globally

Express Pharma

NOVEMBER 1, 2023

Since 2002, Science has been studying the best organisations in biotech, pharma, and biopharma as part of its Top Employers Survey. Based in the United States, Science is the peer-reviewed academic journal of the American Association for the Advancement of Science (AAAS) and one of the world’s top academic journals.

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

FEBRUARY 14, 2023

OTX-2002, the first mRNA therapy to target c-Myc (MYC) oncogene overexpression, could be the first programmable epigenetic medicine.” ” OTX-2002, the first mRNA therapy to target c-Myc (MYC) oncogene overexpression, could be the first programmable epigenetic medicine, with the potential to generate $1.6

Vaccines

Vaccines Immunity Immunization

SAEM Clinical Images Series: An Ultrasonographic Rabbit Hole

ALiEM - Pharm Pearls

FEBRUARY 16, 2024

2002), Role of sonography in the diagnosis of gallbladder perforation. 1983 Jul;148(1):219-21. doi: 10.1148/radiology.148.1.6856839. 148.1.6856839. PMID: 6856839. Khandelwal, N. and Suri, S. Ultrasound, 30: 270-274.

Hospitals

BDR Pharmaceuticals- Openings for Production/ QA/ QC/ CVC/ Packing/ Engineering- Apply Now

Pharma Pathway

JANUARY 31, 2023

BDR Pharmaceuticals- Openings for Production/ QA/ QC/ CVC/ Packing/ Engineering- Apply Now Job Description BDR Pharmaceuticals was Established in 2002 into API manufacturing, We have a consolidated position in the domestic and global market for the API Business.

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

DECEMBER 14, 2022

Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. That’s an objectively long time to have exclusivity of a drug that was first synthesised nearly 100 years ago.

Controlled Substances

Dr Reddy’s Laboratories among top 15 biotech and pharma employers in Science Magazine Survey

Express Pharma

OCTOBER 25, 2024

based peer-reviewed journal of the American Association for the Advancement of Science (AAAS), has conducted this Top Employers Survey annually since 2002, evaluating the leading organisations in the biotech, pharma, and biopharma fields. Science , a U.S.-based

BDR Pharmaceuticals-Walk-In Drive for Production/ QA/ QC/ ADL/ Engineering On 25th Feb’ 2023

Pharma Pathway

FEBRUARY 23, 2023

BDR Pharmaceuticals-Walk-In Drive for Production/ QA/ QC/ ADL/ Engineering On 25th Feb’ 2023 Job Description BDR Pharmaceuticals was Established in 2002 into API manufacturing, We have a consolidated position in the domestic and global market for the API Business.

Adalimumab biosimilars shaping market, research states

European Pharmaceutical Review

AUGUST 4, 2023

billion in 2022, a product that was launched in 2002. There are at present, nine US Food and Drug Administration (FDA)-approved agents, GlobalData stated. Worldwide sales for Humira peaked at $21.2 percent in the first quarter compared to the same time last year.

Biosimilars

PTAB Institutes Sarepta’s IPR

Big Molecule Watch

SEPTEMBER 6, 2024

10405–10410 (2002) (“Xie”), Stephen Snowdy, Nuclear targeting by adeno-associated virus capsid proteins and virions (2003) (Ph.D. The PTAB now has granted institution of Sarepta’s IPR, which challenges claims 1, 3-6, and 8 of the ’274 patent as obvious over four prior art references: US 2003/0138772 A1 (“’772 Publication”), Qing Xie et al.,

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

SEPTEMBER 1, 2023

OTX-2002 from Omega Therapeutics is an mRNA therapy anticipated to generate $658 million in global sales, representing 33.2 It will open new opportunities to boost the potential of mRNA-based therapies by combining them with other ICIs and expanding to other solid tumours, GlobalData stated. “ percent of the total mRNA therapy market by 2029.

Immunity

Immunity Immunization Vaccines

Cheryl Barton

pharmaphorum

AUGUST 7, 2024

In 2002, Dr Barton founded PharmaVision to provide independent, tailor-made, life sciences, and consumer health research to pharmaceutical companies, competitive intelligence specialists, investment institutions, and healthcare communication agencies.

Communication

Communication Pharmaceutical Companies Pharmaceutical Companies

Personalizing the Cancer Patient Journey

Pharma Marketing Network

JULY 27, 2022

Reach out at swhite@xaviercreative.com. Connect at linkedin.com/in/sunnywhite/ . REFERENCES: Organization, World Health. The IMPORTANCE of PHARMACOVIGILANCE Safety Monitoring of Medicinal Products. Accessed June 18, 2022. The post Personalizing the Cancer Patient Journey appeared first on Pharma Marketing Network.

Communication

AbbVie’s immunology portfolio to offset Humira losses: GlobalData

Express Pharma

MAY 29, 2024

From its 2002 FDA approval to 2023, Humira generated $187 billion for AbbVie. These products are forecast to collectively generate over $32 billion by 2030, enabling AbbVie to financially rebound and continue its position as a leading immunology player, says GlobalData.

Biosimilars

BioNTech to lead $2 bn mRNA-based oncology therapy market despite challenges: GlobalData

Express Pharma

AUGUST 31, 2023

OTX-2002 from Omega Therapeutics is an mRNA therapy anticipated to generate $658 million in global sales, representing 33.2 Dr Biswajit Podder, Oncology and Hematology Analyst at GlobalData, comments, “mRNA-based therapies have the potential to revolutionize cancer treatment. per cent of the total mRNA therapy market by 2029.

Immunity

Immunity Immunization Vaccines

Michael Reilly: Congress Should Maintain Current FDA Biosimilars Standards

Safe Biologics

SEPTEMBER 27, 2024

Department of Health and Human Services from 2002-2008, including three years as Associate Deputy Secretary. A failure to do so will put patient health outcomes, and physician trust in these important medicines, in jeopardy. Michael Reilly served in the Office of the Secretary of the U.S. Read the oped at RealClearHealth

Biosimilars

Boehringer’s Cyltezo illustrates intersection of price and regulation in biosimilar market: GlobalData

Express Pharma

AUGUST 1, 2023

Humira has long been a very profitable asset for AbbVie, with steadily rising annual US sales since its launch in 2002; peaking at $18.6 Against this backdrop, Cyltezo from Boehringer Ingelheim has shown the intersection of price and regulation in the biosimilar market, says GlobalData. billion in 2022 ($21.2 billion global).

Biosimilars

EU proposes new blood, tissues and cells Regulation

European Pharmaceutical Review

JULY 25, 2022

The new Regulation will replace the rules for safety and quality set out in Directives 2002/98/EC for blood and blood components and 2004/23/EC for tissues and cells, in addition to their implementing acts. .

Tinnitus

RX Note

MARCH 31, 2024

Effect of melatonin on tinnitus, 1998 The role of zinc in management of tinnitus, 2002 Ginkgo biloba for tinnitus, 2013 Zinc supplementation for tinnitus, 2016 Ginkgo biloba for tinnitus, 2022 External Links Effect of melatonin on tinnitus, 1998 A meta-analytic review of psychological treatments for tinnitus, 1999 The role of zinc in management of (..)

Community Pharmacies

Healthware Group announces acquisition of Argon Global Healthcare network

pharmaphorum

MARCH 2, 2022

” Established in 2002, Argon Global Healthcare has built a global healthcare agency network covering major markets in EMEA, Americas, and APAC. This robust network comprises independently owned healthcare communications agencies with a proven track record of high performance.

Communication

Porterhouse Medical Group joins imc group

pharmaphorum

AUGUST 19, 2020

Founded by Hallows and Brian Parsons in 2002, the Reading, UK-headquartered Porterhouse is a healthcare communications and insights research agency that provides scientific and medical expertise to the global pharmaceutical industry.

Communication

Lupin acquires nine brands of Medical Nutritional Institute in South Africa

Express Pharma

OCTOBER 4, 2024

MNI’s unique plant-based formulations, developed in 2002 by a team of healthcare professionals, have been extensively tested to ensure their efficacy.” Mariaan du Plessis, CEO of MNI , shared her excitement about joining Pharma Dynamics. “We

Diabetes

Diabetes Immunity Immunization

Surprise pandemic lessons for pharma

pharmaphorum

JULY 30, 2021

Residents of Southeast Asia who had experienced the SARS outbreak in 2002-04 would likely have had a much better understanding, but even they could not have imagined just how disorganised the response would be in many other parts the world.

Vaccines

REGiMMUNE Entered into a License Agreement with San Fu Biotech to Develop and Commercialize RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease

PharmaShots

APRIL 3, 2023

REGiMMUNE’s RGI-2001 is currently in P-III trial for the prophylaxis of aGVHD Ref: Businesswire | Image: Regimmune Related News:- Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

GPAT TEST QUIZ 02

PharmaState Academy

FEBRUARY 8, 2024

Do This and No Matter Where You Are, You Will Have Nothing To Fear.” – The Cat Returns (2002) Note: You can participate only 1 time. "Always Believe In Yourself. Participation by using another name & email id will lead to disqualification. The winner will be announced after profile verification.

Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape

Pharmaceutical Technology

AUGUST 17, 2022

A vaccine called Lymerix , then manufactured by SmithKline Beecham, was approved in the US in 1998 but was quickly withdrawn in 2002 due to insufficient custo mer demand. Lyme disease is also known as borreliosis, which refers to the borrelia bacteria that cause the condition. It is currently treated with antibiotics.

Vaccines

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Eye on FDA

AUGUST 2, 2022

By 2002, the number had dropped to 28, reviving somewhat by the end of that decade when it reached 52 in 2010. But when it comes to enforcement things have changed greatly over the years. In 1998, there were 156 letters issued in a single year.

Communication

Communication Pharmaceutical Companies Pharmaceutical Companies Documentation

Three strategies for managing loss of exclusivity successfully

pharmaphorum

FEBRUARY 18, 2021

6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002. RESULT: As of 2002, 40% of PRILOSEC patients had switched to NEXIUM, which notched up sales of $3.9 Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. billion in 2004.14

Prescription Filling

Prescription Filling Drug Pricing Biosimilars Compounding

Dandruff

RX Note

JULY 16, 2023

External Links A randomized, controlled clinical trial of four anti-dandruff shampoos, 1981 Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments, 2001 A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic (..)

Community Pharmacies

A history of blood cancer treatment

pharmaphorum

SEPTEMBER 13, 2022

2002 – Emergence of CAR-T therapy. It wasn’t until 2002, when Memorial Sloane Kettering Cancer Center scientists Michel Sadelain, Renier Brentjens, and Isabelle Rivière opted to push the boundaries of research, by genetically engineering T-cells with a CAR, that the technique achieved successful results.

Chemotherapy

Chemotherapy Immunity Immunization Documentation

Sore Throat

RX Note

NOVEMBER 3, 2023

, 2000 Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain, 2002 Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept, 2002 Flurbiprofen: new indication. Lozenges: NSAIDs are not to be taken like sweets!,

Immunity

Immunity Immunization Community Pharmacies

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

SEPTEMBER 14, 2023

2 By comparison, the American Society of Health-System Pharmacists (ASHP) identified only 224 drug shortages during the entire six-year period between January 1996 and June 2002. EMA prepares for winter antibiotic shortages That slowdown resulted in 211 drug shortages in 2010—the highest number recorded in a single year at the time.

Drug Development

Drug Development Drug Pricing Communication

A history of Johnson & Johnson

pharmaphorum

FEBRUARY 26, 2021

Weldon became the Chairman and CEO of J&J in 2002. The litigation was settled in 2009, when Boston Scientific agreed to pay $716 million in September and an additional $1.73 billion the following February. Under his leadership, the company entered new therapeutic areas.

Vaccines

STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

Opinion: What Rosalynn Carter understood about mental health

Trending Sources

Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s

STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug

Watch: Blockbuster drug Humira has new competition. Here’s why that matters

STAT+: Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts

Watch: Blockbuster drug Humira has new competition. Here’s why that matters

How telehealth startups are trying to fill the menopause care vacuum

First patient receives new engineered mRNA epigenetic

Leprosy potentially endemic in Central Florida

Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

AGI Greenpac gets CCI approval to acquire Hindustan National Glass & Industries

Science Magazine names Dr Reddy’s among Top 20 employers in pharma globally

Key developments: mRNA vaccines and therapeutics

SAEM Clinical Images Series: An Ultrasonographic Rabbit Hole

BDR Pharmaceuticals- Openings for Production/ QA/ QC/ CVC/ Packing/ Engineering- Apply Now

Competition is on the horizon for costly narcolepsy treatments

Dr Reddy’s Laboratories among top 15 biotech and pharma employers in Science Magazine Survey

BDR Pharmaceuticals-Walk-In Drive for Production/ QA/ QC/ ADL/ Engineering On 25th Feb’ 2023

Adalimumab biosimilars shaping market, research states

PTAB Institutes Sarepta’s IPR

$2 billion mRNA-based oncology therapy market anticipated by 2029

Cheryl Barton

Personalizing the Cancer Patient Journey

AbbVie’s immunology portfolio to offset Humira losses: GlobalData

BioNTech to lead $2 bn mRNA-based oncology therapy market despite challenges: GlobalData

Michael Reilly: Congress Should Maintain Current FDA Biosimilars Standards

Boehringer’s Cyltezo illustrates intersection of price and regulation in biosimilar market: GlobalData

EU proposes new blood, tissues and cells Regulation

Tinnitus

Healthware Group announces acquisition of Argon Global Healthcare network

Porterhouse Medical Group joins imc group

Lupin acquires nine brands of Medical Nutritional Institute in South Africa

Surprise pandemic lessons for pharma

REGiMMUNE Entered into a License Agreement with San Fu Biotech to Develop and Commercialize RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease

GPAT TEST QUIZ 02

Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Three strategies for managing loss of exclusivity successfully

Dandruff

A history of blood cancer treatment

Sore Throat

Achieving scale up success under economic uncertainty

A history of Johnson & Johnson

Stay Connected